AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$MGNX

Peters Jeffrey Stuart sold $129K of MGNX

Peters Jeffrey Stuart (Senior VP, GC, and Secretary) sold 31,105 shares of MACROGENICS INC (MGNX) at $4.15 ($0.13M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Peters Jeffrey Stuart
Published Aug 20, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MGNX
Bearish
medium confidence
Mentioned
$MGNX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGNXBearishLow
01

Why it matters

A small insider divestiture by a senior officer may cause slight short‑term price weakness but is unlikely to drive major moves.

02

Market read

Primary disclosure of a modest insider sale; limited trading relevance.

03

What to watch

The 10b5‑1 plan may have been pre‑scheduled, limiting informational value.

Relevance 3/10Novelty 4/10Timing: filed after market close on 2026-08-20

Background

Form 4 filings disclose insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$MGNXBearishMedium confidence
Context

Senior VP Jeffrey Stuart sold 31,105 shares for $129,085 via a 10b5‑1 plan, reducing his holding to zero.

Expected impact

Potential modest downside pressure in the next trading session.

Evidence & confidence

Insider sales, especially by a senior officer, often lead to slight sell‑offs, but the amount is small relative to market cap.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale activity.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine estate planning, not a negative signal.

Key entities

  • Company
    MacroGenics Inc.

    Biotech firm listed on NASDAQ under ticker MGNX.

  • Individual
    Jeffrey Stuart

    Senior Vice President, General Counsel and Secretary of MacroGenics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MGNX insider trading history →

Related articles

OCT 23
$MGNXMedAI 8/10

MacroGenics reports phase 1 data for MGC026 in solid tumors

MacroGenics Inc. (MGNX) reported phase 1 trial data for MGC026, an antibody-drug conjugate targeting B7-H3, in advanced solid tumors. 85 patients were enrolled, with 29% response rate in dose-escalation and 27% in head and neck cancer cohort. Grade 3+ adverse events occurred in 51% of patients, with no grade 5 events. The company plans further trials with pembrolizumab in 2027.

investing.com2 min
OCT 23
$MGNXMedAI 8/10

Tumors shrank in 6 of 22 patients with head and neck cancer; 2 responses to the experimental drug were unconfirmed.

MacroGenics (MGNX) reported positive interim Phase 1 data for MGC026, its B7-H3-directed antibody-drug conjugate, showing a 27% overall response rate in 22 heavily pretreated SCCHN patients. The drug demonstrated manageable safety and tolerability. The company plans to initiate a front-line SCCHN cohort evaluating MGC026 in combination with pembrolizumab in early 2027. Data were presented at the ESMO 2026 Congress.

stocktitan.net2 min
AUG 13
$MGNXMed

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position • Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately

SEC EDGAR 8-K6 min
AUG 11
$MGNXMed

MacroGenics stock rises on $10M Gilead option exercise

MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.

investing.com2 min
JUL 7
$MGNXMed

MACROGENICS INC (MGNX): Completion of Acquisition or Disposition of Assets

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and

SEC EDGAR 8-K4 min